What’s MabVax Therapeutics Holdings, Inc. (MBVX) Downside After Touching 1 Year Low?

April 24, 2018 - By Linda Rogers

MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) Logo

The stock of MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) hit a new 52-week low and has $1.09 target or 4.00 % below today’s $1.14 share price. The 6 months bearish chart indicates high risk for the $10.22M company. The 1-year low was reported on Apr, 24 by Barchart.com. If the $1.09 price target is reached, the company will be worth $408,640 less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 2.56% or $0.03 during the last trading session, reaching $1.14. About 76,868 shares traded. MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) has declined 77.12% since April 24, 2017 and is downtrending. It has underperformed by 88.67% the S&P500.

MabVax Therapeutics Holdings, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has market cap of $10.22 million. The firm has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. It currently has negative earnings. The Company’s lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are in proof of concept Phase II multi-center clinical trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.